Thyroid Disorder Market

ID: MRFR/Pharma/2031-CR
118 Pages
Satyendra Maurya
Last Updated: May 15, 2026
Thyroid Disorder Market Research Report Information by Type (Hypothyroidism and Hyperthyroidism), Treatment (Medications, Radioactive Iodine Therapy, and Surgery), Route of Administration (Oral, Intravenous and others), End-User (Hospitals, Clinics, and others) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) - Forecast till 2035
Thyroid Disorder Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.2%
2024 Market Size$ 2.51 Billion
2025 Market Size$ 2.62 Billion
2035 Market Size$ 3.95 Billion
Key Players
AbbVie
Bristol-Myers Squibb
Eli Lilly and Company
Merck & Co.
Novartis
Pfizer
Trends
  • Increased Awareness and Screening
  • Technological Advancements in Treatment
  • Focus on Personalized Medicine
Opportunities
  • Rising Healthcare Expenditure
  • Growing Demand for Targeted Therapies
  • Rising Incidence of Thyroid Disorders
Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Thyroid Disorder Type Outlook (USD Billion)
      1. 4.1.1 Hypothyroidism
      2. 4.1.2 Hyperthyroidism
    2. 4.2 Healthcare, BY Thyroid Disorder Treatment Outlook (USD Billion)
      1. 4.2.1 Medications
      2. 4.2.2 Surgery
      3. 4.2.3 Radioactive iodine therapy
    3. 4.3 Healthcare, BY Thyroid Disorder Route of Administration Outlook (USD Billion)
      1. 4.3.1 Intravenous
      2. 4.3.2 Oral
      3. 4.3.3 Other
    4. 4.4 Healthcare, BY Thyroid Disorder End-User Outlook (USD Billion)
      1. 4.4.1 Clinics
      2. 4.4.2 Hospitals
      3. 4.4.3 Others
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AbbVie (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Eli Lilly and Company (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Novartis (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Takeda Pharmaceutical Company (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Amgen (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    4. 6.4 US MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    5. 6.5 US MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    6. 6.6 US MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    7. 6.7 CANADA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    8. 6.8 CANADA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    9. 6.9 CANADA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    10. 6.10 CANADA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    13. 6.13 GERMANY MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    14. 6.14 GERMANY MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    15. 6.15 GERMANY MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    16. 6.16 UK MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    17. 6.17 UK MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    18. 6.18 UK MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    19. 6.19 UK MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    20. 6.20 FRANCE MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    21. 6.21 FRANCE MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    22. 6.22 FRANCE MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    23. 6.23 FRANCE MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    24. 6.24 RUSSIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    25. 6.25 RUSSIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    26. 6.26 RUSSIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    27. 6.27 RUSSIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    28. 6.28 ITALY MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    29. 6.29 ITALY MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    30. 6.30 ITALY MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    31. 6.31 ITALY MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    32. 6.32 SPAIN MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    33. 6.33 SPAIN MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    34. 6.34 SPAIN MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    35. 6.35 SPAIN MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    42. 6.42 CHINA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    43. 6.43 CHINA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    44. 6.44 CHINA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    45. 6.45 INDIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    46. 6.46 INDIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    47. 6.47 INDIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    48. 6.48 INDIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    49. 6.49 JAPAN MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    50. 6.50 JAPAN MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    51. 6.51 JAPAN MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    52. 6.52 JAPAN MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    57. 6.57 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    58. 6.58 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    59. 6.59 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    60. 6.60 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    61. 6.61 THAILAND MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    62. 6.62 THAILAND MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    63. 6.63 THAILAND MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    64. 6.64 THAILAND MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    65. 6.65 INDONESIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    66. 6.66 INDONESIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    67. 6.67 INDONESIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    68. 6.68 INDONESIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    69. 6.69 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    70. 6.70 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    71. 6.71 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    72. 6.72 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    75. 6.75 BRAZIL MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    76. 6.76 BRAZIL MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    77. 6.77 BRAZIL MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    78. 6.78 MEXICO MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    79. 6.79 MEXICO MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    80. 6.80 MEXICO MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    81. 6.81 MEXICO MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    82. 6.82 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    83. 6.83 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    84. 6.84 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    85. 6.85 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    99. 6.99 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    100. 6.100 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    101. 6.101 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    102. 6.102 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY THYROID DISORDER TYPE OUTLOOK, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY THYROID DISORDER TYPE OUTLOOK, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY THYROID DISORDER TREATMENT OUTLOOK, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY THYROID DISORDER TREATMENT OUTLOOK, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY THYROID DISORDER END-USER OUTLOOK, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY THYROID DISORDER END-USER OUTLOOK, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.2.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.2.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.2.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.3.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.3.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.3.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.4.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.4.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.4.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.5.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.5.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.5.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.6.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.6.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.6.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.7.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.7.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.7.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.8.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.8.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.8.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.9.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.9.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.9.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.10.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.10.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.10.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.11.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.11.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.11.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.12.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.12.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.12.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.13.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.13.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.13.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.14.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.14.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.14.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.15.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.15.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.15.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.16.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.16.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.16.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.17.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.17.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.17.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.18.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.18.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.18.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.19.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.19.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.19.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.20.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.20.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.20.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.21.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.21.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.21.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.22.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.22.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.22.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.23.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.23.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.23.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.24.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.24.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.24.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.25.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.25.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.25.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.26.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.26.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.26.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.27.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.27.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.27.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.28.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.28.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.28.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.29.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.29.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.29.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
      2. 7.30.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
      3. 7.30.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
      4. 7.30.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Thyroid Disorder Market Segmentation

Thyroid Disorder Market By Thyroid Disorder Type Outlook (USD Billion, 2025-2035)

  • Hypothyroidism
  • Hyperthyroidism

Thyroid Disorder Market By Thyroid Disorder Treatment Outlook (USD Billion, 2025-2035)

  • Medications
  • Surgery
  • Radioactive iodine therapy

Thyroid Disorder Market By Thyroid Disorder Route of Administration Outlook (USD Billion, 2025-2035)

  • Intravenous
  • Oral
  • Other

Thyroid Disorder Market By Thyroid Disorder End-User Outlook (USD Billion, 2025-2035)

  • Clinics
  • Hospitals
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.